不同化疗方案治疗华氏巨球蛋白血症的临床疗效  

Clinical efficacy of different chemotherapy regimens in treating Waldenstrm's macroglobulinemia

作　　者：植立婷 仇惠英[1] 陈苏宁[1] 傅铮铮[1] 金正明[1] 孙爱宁[1] 吴德沛[1] 

机构地区：[1]苏州大学附属第一医院血液病科,江苏省215006

出　　处：《江苏医药》2016年第12期1351-1353,共3页Jiangsu Medical Journal

基　　金：江苏省科教兴卫工程-临床医学中心资助项目(ZX201102);江苏省血液病临床医学研究中心资助项目(江苏省科技厅生命健康专项-BL2012005)

摘　　要：目的探讨不同化疗方案治疗华氏巨球蛋白血症(WM)的临床疗效。方法将15例WM患者随机分为利妥昔单抗联合环磷酰胺为基础的化疗组(A组,8例)和氟达拉滨为基础的化疗组(B组,7例),比较两组化疗疗效和生存时间。结果 A组治疗后完全缓解(CR)1例,部分缓解(PR)5例,微小缓解(MR)1例,疾病稳定(SD)1例;B组治疗后CR 2例,PR 3例,MR 1例,SD1例。随访期间,A组患者生存率高于B组(100%vs.28.6%)(P<0.05)。结论利妥昔单抗联合环磷酰胺为基础的化疗方案在WM中的治疗效果优于氟达拉滨为基础的化疗方案。Objective To investigate the clinical efficacy of different chemotherapy regimens in the treatment of Waldenstrom＇s macroglobulinemia （WM）. Methods Fifteen patients with WM were randomly divided into two groups of A （treated with rituximab in combination of cyclophosphamide-based chemotherapy,8 cases） and B（treated with fludarabine-based chemotherapy, 7 cases）. The efficacy and survival time between two groups were compared. Results Complete remission（CR） was seen in 1 case,partial remission（PR） in 5 cases, minor remission（MR） in 1 case and stable disease（SD） in 1 case in group A. Group B had CR in 2 cases,PR in 3 cases,MR in 1 case and SD in 1 case. The survival rate during follow-up was higher in group A than that in group B （100 % vs. 28.6 %） （P〈0.05）. Conclusion Combined use of rituximab and cyclophosphamide-based chemotherapy regimen in the treatment of WM achieves a better result than fludarabine-based chemotherapy regimen.

关 键 词：华氏巨球蛋白血症 利妥昔单抗 环磷酰胺 氟达拉滨 

分 类 号：R453[医药卫生—治疗学]